PACAP and its receptor VPAC1 regulate megakaryocyte maturation: Therapeutic implications

Blood

Volumn 111, Issue 4, 2008, Pages 1885-1893

  Freson, Kathleen ^a   Peeters, Karen ^a   De Vos, Rita ^b   Wittevrongel, Christine ^a   Thys, Chantal ^a   Hoylaerts, Marc F ^a   Vermylen, Jos ^a   Van Geet, Chris ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE ACTIVATOR; CD34 ANTIGEN; CYCLIC AMP; FORSKOLIN; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 23A11; MONOCLONAL ANTIBODY PP1A4; NEUTRALIZING ANTIBODY; THROMBOPOIETIN; TRANSCRIPTION FACTOR GATA 1; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW; BONE MARROW SUPPRESSION; CELL DIFFERENTIATION; CELL MATURATION; CONTROLLED STUDY; DISEASE SEVERITY; GENE EXPRESSION; GENE OVEREXPRESSION; HEMATOPOIETIC STEM CELL; HUMAN; IN VITRO STUDY; MALE; MEGAKARYOCYTE; MEGAKARYOPOIESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; RABBIT; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; THROMBOCYTE ANOMALY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TRANSGENIC MOUSE; TRISOMY; TRISOMY 18P; WILD TYPE;

EID: 41349093354     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-06-098558     Document Type: Article

References (35)

1. Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, Vaudry H. Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharm Rev. 2000;52:269-324.
2. Gozes I, Furman S. VIP and drug design. Curr Pharm Des. 2003;9:483-494.
3. Laburthe M, Couvineau A, Marie JC. VPAC receptors for VIP and PACAP Receptors Channels. 2002;8:137-153.
4. Hosoya M, Kimura C, Ogi K, et al. Structure of the human pituitary adenylate cyclase-activating polypeptide (PACAP) gene. Biochim Biophys Acta. 1992;1129:199-206.
5. Banks WA, Kastin AJ, Komaki G, Arimura A. Passage of pituitary adenylate cyclase activating polypeptide1-27 and pituitary adenylate cyclase activating polypeptide1-38 across the blood-brain barrier. J Pharmacol Exp Ther. 1993;267:690-696.
6. Freson K, Hashimoto H, Thys C, et al. The pituitary adenylate cyclase-activating polypeptide is a physiological inhibitor of platelet activation. J Clin Invest. 2004;113:905-912.
7. Kaushansky K. Thrombopoietin: the primary regulator of platelet production. Blood. 1995;86:419-431.
8. Kaushansky K. The molecular mechanisms that control thrombopoiesis. J Clin Invest. 2005;115:3339-3347.
9. Weich NS, Fitzgerald M, Wang A, et al. Recombinant human interleukin-11 synergizes with steel factor and interleukin-3 to promote directly the early stages of murine megakaryocyte development in vitro. Blood. 2000;95:503-509.
10. Broudy V, Lin NL, Kaushansky K. Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro. Blood. 1995;85:1719-1726.
11. Schulze H, Shivdasani RA. Mechanisms of thrombopoiesis. J Thromb Haemost. 2005;3:1717-1724.
12. Orkin SH, Shivdasani RA, Fujiwara Y, McDevitt MA. Transcription factor GATA-1 in megakaryocyte development. Stem Cells. 1998;16:79-83.
13. Chang AN, Cantor AB, Fujiwara Y, et al. GATA-factor dependence of the multitype zinc-finger protein FOG-1 for its essential role in megakaryopoiesis. Proc Natl Acad Sci U S A. 2002;99:9237-9242.
14. Majka M, Janowska-Wieczorek A, Ratajczak J, et al. Stromal-derived factor 1 and thrombopoietin regulate distinct aspects of human megakaryopoiesis. Blood. 2000;96:4142-4151.
15. Park SK, Olson TA, Ercal N, Summers M, O'Dorisio MS. Characterization of vasoactive intestinal peptide receptors on human megakaryocytes and platelets. Blood. 1996;87:4629-4635.
16. Rameshwar P, Gascon P, Oh HS, Denny TN, Zhu G, Ganea D. Vasoactive intestinal peptide (VIP) inhibits the proliferation of bone marrow progenitors through the VPAC1 receptor. Exp Hematol. 2002;30:1001-1009.
17. Freson K, Matthijs G, Thys C, et al. Different substitutions at residue D218 of the X-linked transcription factor GATA1 lead to altered clinical severity of macrothrombocytopenia and anemia and are associated with variable skewed X inactivation. Hum Mol Genet. 2002;11:147-152.
18. Shivdasani RA, Fujiwara Y, McDevitt MA, Orkin SH. A lineage-selective knockout establishes the critical role of transcription factor GATA-1 in megakaryocyte growth and platelet development. EMBO J. 1997;16:3965-3973.
19. Vyas P, Ault K, Jackson CW, Orkin SH, Shivdasani RA. Consequences of GATA-1 deficiency in megakaryocytes and platelets. Blood. 1999;93:2867-2875.
20. Freson K, Jaeken J, Van Helvoirt M, et al. Functional polymorphisms in the paternally expressed XLalphas and its cofactor ALEX decrease their mutual interaction and enhance receptor-mediated cAMP formation. Hum Mol Genet. 2003;12:1121-1130.
21. Mathur A, Hong Y, Wang G, Erusalimsky JD. Assays of megakaryocyte development: surface antigen expression, ploidy, and size. Methods Mol Biol. 2004;272:309-322.
22. Kuter DJ, Rosenberg RD. The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit. Blood. 1995;85:2720-2730.
23. Leytin V, Allen DJ, Mody M, et al. A rabbit model for monitoring in vivo viability of human platelet concentrates using flow cytometry. Transfusion. 2002;42:711-718.
24. Rothwell SW, Maglasang P, Krishnamurti C. Survival of fresh human platelets in a rabbit model as traced by flow cytometry. Transfusion. 1998;38:550-556.
25. Knudsen SM, Tams JW, Fahrenkrug J. Role of second extracellular loop in the function of human vasoactive intestinal polypeptide/pituitary adenylate cyclase activating polypeptide receptor 1 (hVPAC1R). J Mol Neurosci. 2000;14:137-146.
26. Lelievre V, Meunier AC, Caigneaux E, Falcon J, Muller J. Differential expression and funcion of PACAP and VIP receptors in four human colonic adenocarcinoma cell lines. Cell Signal. 1998;10:13-26.
27. Ohwada A, Rafii S, Moore MA, Crystal RG. In vivo adenovirus vector-mediated transfer of the human thrombopoietin cDNA maintains platelet levels during radiation-and chemotherapy-induced bone marrow suppression. Blood. 1996;88:778-784.
28. Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood. 2002;100:3457-3469.
29. Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood. 2001;98:3241-3248.
30. Yan XQ, Lacey D, Hill D, et al. A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): reversal of disease by bone marrow transplantation. Blood. 1996;88:402-409.
31. Vaudry D, Chen Y, Ravni A, Hamelink C, Elkahloun AG, Eiden LE. Analysis of the PC12 cell transcriptome after differentiation with pituitary adenylate cyclase-activating polypeptide (PACAP). J Neurochem. 2002;83:1272-1284.
32. Grumolato L, Elkahloun AG, Ghzili H, et al. Microarray and suppression subtractive hybridization analyses of gene expression in pheochromocytoma cells reveal pleiotropic effects of pituitary adenylate cyclase-activating polypeptide on cell proliferation, survival, and adhesion. Endocrinology. 2003;144:2368-2379.
33. Kasper LH, Boussouar F, Ney PA, et al. A transcription-factor-binding surface of coactivator p300 is required for haematopoiesis. Nature. 2002;419:738-743.
34. Tomer A. Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia. Blood. 2002;99:1602-1609.
35. Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood. 2001;97:863-866.